Antengene to Host R&D Day on November 20th, 2025

Shanghai and Hong Kong, PRC, November 10, 2025 — Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it will host its R&D Day in Shanghai on November 20th, 2025, both **in-person** and **online** through webcast. The event will feature updates on Antengene’s the latest clinical data and pipeline developments, as well as an overview of the company’s strategic outlook for 2026.

Date and Time:

November 20 (Thursday), 2:00 PM-5:00 PM (Beijing Time)

Management Team:

Dr. Jay Mei

Founder, Chairman, and CEO

Dr. Godfrey Guo

Vice President, Clinical Development

Dr. Bing Hou

Vice President, Head of Discovery Science and Translational Medicine

Mr. Kavin Cao

Corporate Vice President and Board Secretary

Featured Speaker:

Prof. Dan Cao

Chief, Division of Abdominal Tumor, Department of Medical Oncology; Director, Center for Research on Immune Microenvironment in Abdominal Tumors, West China Hospital, Sichuan University

Ways to Participate:

1. Webcast:

https://s.comein.cn/niydvwtd

2. Conference Call:

(Dial-in From China)

Mainland of China: +86-4001888938

Global: +86-01021377168

(Dial-in From Overseas)

Hong Kong, China: +852-51089680

Hong Kong, China: +852-800931266

Taiwan, China: +886-277083288

United States: +1-2087016888

Global: +86-1021377168

Access Code: 421644

About Antengene

Antengene Corporation Limited (**"Antengene"** , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.